Woodcock defends Biogen's new Alzheimer's drug, says it has more supportive data than many past accelerated approvals

Acting FDA commissioner Janet Woodcock publicly defended Biogen’s controversial Alzheimer’s drug Aduhelm on Tuesday, saying it’s “a very solid” accelerated approval, and “has a lot more supportive data” than many other drugs that have won accelerated approval over the years.